Early access to the machine will be given to AstraZeneca, GlaxoSmithKline and Oxford Nanopore, as well as researchers at Guy's and St Thomas' NHS Foundation Trust and King's College London. "Tackling the world's most pressing challenges in healthcare requires massively powerful computing resources to harness the capabilities of AI," said Jensen Huang, founder and CEO of NVIDIA, in his GPU Technology Conference keynote. "The Cambridge-1 supercomputer will serve as a hub of innovation for the UK, and further the groundbreaking work being done by the nation's researchers in critical healthcare and drug discovery." Supercomputers can aid in drug discovery by using powerful algorithms to analyse millions of chemical compounds in a matter of days. In January, the first drug designed entirely using artificial intelligence (AI) entered clinical human trials in what was described at the time as a major milestone in medicine.